Exparel 266 MG/20 ML vial 20ML
Ended Awarded
- Contract number
- SPE2DB26FKDXU
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $5,021
Award facts
- Contract value 100% obligated
- $5,021.26 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $5,021.26 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for EXPAREL 266 mg/20 ml vials. The delivery order, issued on October 27, 2025, with an ultimate completion date of November 18, 2025, carries no set-aside designation, indicating the vendor competed in an unrestricted federal procurement environment. This award falls under DMS Pharmaceutical Group's recently established Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to supply comprehensive pharmaceutical products and medical consumables to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group serves as a critical supplier within the federal military medical supply chain, leveraging its small business status and established performance record to compete effectively across multiple therapeutic categories. EXPAREL is a specialty surgical product used for pain management during surgical procedures. The company's extensive product portfolio spans branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals, positioning it to fulfill the diverse pharmaceutical requirements of DoD healthcare operations globally. As a single-award prime vendor under the PPV-G GEN V program with a $499.999 billion ceiling value extending through December 31, 2036, DMS Pharmaceutical Group has demonstrated consistent contract performance through numerous delivery orders issued by the Defense Logistics Agency's Medical Supply Chain division.
Quick answers
Who was awarded contract SPE2DB26FKDXU?
SPE2DB26FKDXU was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 27, 2025.
How much is contract SPE2DB26FKDXU worth?
The government has obligated $5,021 on SPE2DB26FKDXU.
Is contract SPE2DB26FKDXU an order under another contract?
Yes. SPE2DB26FKDXU is a delivery order under SPE2DB24D9223, an indefinite delivery contract.
Was contract SPE2DB26FKDXU competed?
The extent of competition for SPE2DB26FKDXU was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award